Immune checkpoint inhibitors have revolutionized the treatment of advanced non-small cell lung cancer, yet the optimal duration of therapy remains uncertain, raising concerns about cumulative toxicity, economic burden, and potential overtreatment. We analyzed ... ...

请注册登录后继续浏览